Loading...
Market
What will be Zunveyl's market share in China among Alzheimer's treatments by end of 2026?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Market analysis reports or industry publications
Story
Alpha Cognition Secures $44 Million Licensing Deal for Alzheimer's Drug Zunveyl in China, Including $6 Million Upfront
Jan 8, 2025, 01:48 PM
Alpha Cognition Inc. has announced a $44 million exclusive licensing agreement for the development and commercialization of Zunveyl, an FDA-approved treatment for mild-to-moderate Alzheimer’s disease, in China. The deal includes a $6 million upfront payment and covers regions including Asia (excluding Japan), Australia, and New Zealand. Zunveyl, also known as benzgalantamine, is anticipated to address neuroinflammation associated with Alzheimer’s disease. This agreement was made with China Medical System, as Alpha Cognition aims to expand its market presence in the Asia-Pacific region.
View original story
Similar markets
Both have equal share • 25%
Leqembi leads • 25%
Donanemab leads • 25%
Other treatments lead • 25%
10% to 20% • 25%
Less than 5% • 25%
More than 20% • 25%
5% to 10% • 25%
Other companies • 25%
Eli Lilly • 25%
Eisai and Biogen • 25%
No dominant company • 25%
More than 30% • 25%
20% to 30% • 25%
10% to 20% • 25%
Less than 10% • 25%
Less than 10% • 25%
More than 30% • 25%
10% to 20% • 25%
20% to 30% • 25%
Less than 10% • 25%
More than 30% • 25%
20% to 30% • 25%
10% to 20% • 25%
Rejected by FDA • 25%
Withdrawn by manufacturer • 25%
Pending approval • 25%
FDA approved and in market • 25%
20% to 30% • 25%
10% to 20% • 25%
Less than 10% • 25%
More than 30% • 25%
Remain the same • 25%
Other • 25%
Decrease • 25%
Increase • 25%
Less than 10% • 25%
More than 30% • 25%
20-30% • 25%
10-20% • 25%